Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

46 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.
Hamilton VH, Racicot FE, Zowall H, Coupal L, Grover SA. Hamilton VH, et al. Among authors: coupal l. JAMA. 1995 Apr 5;273(13):1032-8. JAMA. 1995. PMID: 7897787
The prevalence of erectile dysfunction in the primary care setting: importance of risk factors for diabetes and vascular disease.
Grover SA, Lowensteyn I, Kaouache M, Marchand S, Coupal L, DeCarolis E, Zoccoli J, Defoy I. Grover SA, et al. Among authors: coupal l. Arch Intern Med. 2006 Jan 23;166(2):213-9. doi: 10.1001/archinte.166.2.213. Arch Intern Med. 2006. PMID: 16432091
Do the benefits of finasteride outweigh the risks in the prostate cancer prevention trial?
Grover S, Lowensteyn I, Hajek D, Trachtenberg J, Coupal L, Marchand S. Grover S, et al. Among authors: coupal l. J Urol. 2006 Mar;175(3 Pt 1):934-8; discussion 938. doi: 10.1016/S0022-5347(05)00424-6. J Urol. 2006. PMID: 16469585
Estimating the benefits of patient and physician adherence to cardiovascular prevention guidelines: the MyHealthCheckup Survey.
Grover S, Coupal L, Kouache M, Lowensteyn I, Marchand S, Campbell N. Grover S, et al. Among authors: coupal l. Can J Cardiol. 2011 Mar-Apr;27(2):159-66. doi: 10.1016/j.cjca.2011.01.007. Can J Cardiol. 2011. PMID: 21459263
Preventing cardiovascular disease among Canadians: is the treatment of hypertension or dyslipidemia cost-effective?
Grover S, Coupal L, Lowensteyn I. Grover S, et al. Among authors: coupal l. Can J Cardiol. 2008 Dec;24(12):891-8. doi: 10.1016/s0828-282x(08)70695-0. Can J Cardiol. 2008. PMID: 19052668 Free PMC article.
Determining the cost-effectiveness of preventing cardiovascular disease: are estimates calculated over the duration of a clinical trial adequate?
Grover SA, Coupal L, Lowensteyn I. Grover SA, et al. Among authors: coupal l. Can J Cardiol. 2008 Apr;24(4):261-6. doi: 10.1016/s0828-282x(08)70174-0. Can J Cardiol. 2008. PMID: 18401465 Free PMC article.
Estimating the cost effectiveness of ramipril used for specific clinical indications: comparing the outcomes in four clinical trials with a common economic model.
Grover SA, Coupal L, Lowensteyn I. Grover SA, et al. Among authors: coupal l. Am J Cardiovasc Drugs. 2007;7(6):441-8. doi: 10.2165/00129784-200707060-00007. Am J Cardiovasc Drugs. 2007. PMID: 18076211
Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: the CHECK-UP study: a randomized controlled trial.
Grover SA, Lowensteyn I, Joseph L, Kaouache M, Marchand S, Coupal L, Boudreau G; Cardiovascular Health Evaluation to Improve Compliance and Knowledge Among Uninformed Patients (CHECK-UP) Study Group. Grover SA, et al. Among authors: coupal l. Arch Intern Med. 2007 Nov 26;167(21):2296-303. doi: 10.1001/archinte.167.21.2296. Arch Intern Med. 2007. PMID: 18039987 Clinical Trial.
Preventing cardiovascular disease among Canadians: what are the potential benefits of treating hypertension or dyslipidemia?
Grover SA, Coupal L, Kaouache M, Lowensteyn I. Grover SA, et al. Among authors: coupal l. Can J Cardiol. 2007 May 1;23(6):467-73. doi: 10.1016/s0828-282x(07)70786-9. Can J Cardiol. 2007. PMID: 17487292 Free PMC article.
Cost-effectiveness of lipid-lowering treatment according to lipid level.
Pilote L, Ho V, Lavoie F, Coupal L, Zowall H, Grover SA. Pilote L, et al. Among authors: coupal l. Can J Cardiol. 2005 Jun;21(8):681-7. Can J Cardiol. 2005. PMID: 16003451
46 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback